Loading organizations...
Sorbent Therapeutics has raised $86.0M across 5 funding rounds.
Sorbent Therapeutics has raised $86.0M in total across 5 funding rounds.
Sorbent Therapeutics was a biopharmaceutical company founded in 2005 that developed non-absorbed polymeric drugs for targeted cation and fluid removal from the body, addressing unmet needs in cardiovascular and renal markets like heart failure, chronic kidney disease, and hypertension.[1][2][5] Its lead candidate, CLP-1001, was a polymer designed to bind excess water and sodium in the gastrointestinal tract to treat fluid overload in heart failure patients, with the company enrolling 275 patients in a Phase IIb study; it also advanced CLP-1002 and other therapies through clinical trials.[1][6] The company raised $102.75M in total funding but is now listed as "Dead" or defunct, with no recent activity reported.[1][3]
Headquartered in Sunnyvale, California, Sorbent served patients with cardio-renal conditions but ceased operations, solving problems like fluid management without systemic absorption of drugs.[1][2]
Sorbent Therapeutics was founded in 2005 in Sunnyvale, California, as a private biopharmaceutical venture focused on polymeric therapies for renal and cardiovascular diseases.[1][2] Key details on specific founders are not available in public records, but the company emerged to tackle large unmet needs in heart failure and chronic kidney disease through non-absorbed drugs that act in the gut.[1][5] Early traction included multiple funding rounds, culminating in a $6.5M Series D in 2014 from investors like ARCH Venture Partners, Sofinnova Ventures, Novartis Venture Funds, CMEA Capital, and AgeChem Venture Fund, alongside clinical progress such as the Phase IIb trial for CLP-1001.[1][3] Pivotal moments involved advancing a pipeline including CLP-1001 and CLP-1002 through at least five clinical trials, though it ultimately shut down.[6]
Sorbent rode the early 2000s-2010s wave of targeted therapies for chronic cardio-renal diseases, where fluid management remained a challenge amid rising heart failure prevalence driven by aging populations and comorbidities.[1] Timing aligned with advances in polymer-based drug delivery, filling gaps in non-invasive treatments before oral fluid-targeting therapies gained traction; market forces like high unmet needs in hypertension and CKD (large addressable markets) favored its approach.[2][5] Though defunct, Sorbent influenced the ecosystem by validating GI-acting polymers, paving the way for similar platforms in modern biotech pipelines from companies like Intarcia Therapeutics or Aderis Pharmaceuticals targeting overlapping cardio-renal spaces.[1]
Sorbent Therapeutics represents a cautionary tale of biotech promise unmet, with its innovative polymeric platform stalling post-Phase II amid funding challenges common in the sector. No revival appears likely given its "Dead" status, but its tech could resurface through IP licensing or acquisition as oral therapies for fluid overload evolve with trends like precision medicine and gut-targeted delivery. Its legacy underscores investor interest in renal-cardio innovation, potentially shaping successors in a market still seeking non-diuretic alternatives.[1][3]
Sorbent Therapeutics has raised $86.0M in total across 5 funding rounds.
Sorbent Therapeutics's investors include ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners.
Sorbent Therapeutics has raised $86.0M across 5 funding rounds. Most recently, it raised $7.0M Series D in May 2014.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2014 | $7.0M Series D | ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners | |
| Mar 1, 2013 | $3.0M Venture Round | ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners | |
| Aug 1, 2012 | $18.0M Series C | ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners | |
| Jun 1, 2011 | $36.0M Series B | ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners | |
| Sep 1, 2010 | $22.0M Series B | ARCH Venture Partners, Flagship Ventures, NanoDimension, Polaris Partners |